1. Distribution of 5-HT1B and 5-HT1D receptors in the brain and trigeminal ganglia, measurement of receptor occupancy in the guinea-pig brain treated with alniditan, sumatriptan and dihydroergotamine;Bonaventura;Cephalalgia,1997
2. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels;Bouchelet;Mol. Pharmacol.,1996
3. Evolution of a novel series of [(N,N-dimethylamino)propyl]- and piperazinylbenzanilides as the first selective 5-HT1D antagonists;Clitherow;J. Med. Chem.,1994
4. An alniditan (Pasmigren(r)) trial (ALN-INT-12*) re-assessed using a more stringent efficacy end-point: 24 h pain-free;Dahlöf;Cephalalgia,1997
5. Blockade of porcine carotid vascular response to sumatriptan by GR127935, a selective 5-HT1D receptor antagonist;De Vries;Br. J. Pharmacol.,1996